Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as L606 inhalation suspension, Treprostinil Liposome Inhalation Suspension
L606 · 2 trials · 3 indications
(MSP for Cohort A): Proportion of patients with PAH or PH-ILD on a stable Tyvaso dose who would develop treatment-emergent AEs/SAEs after switching to L606 dosing for up to 2 weeks during MSP.
(OEP for Cohorts A and B): Proportion of subjects with PAH or PH-ILD, choosing to continue twice daily L606 dosing for up to 48 weeks, who would develop treatment emergent AEs/SAEs up to 48 hours after the last dose.
| Arm | Type | Description |
|---|---|---|
| L606 (in combination with nebulizer) | EXPERIMENTAL | - |
| Placebo (in combination with nebulizer) | PLACEBO_COMPARATOR | - |
| L606 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| L606 | DRUG | L606 is a liposomal version of treprostinil intended for delivery via oral inhalation using a study issued nebulizer. |
| Placebo | DRUG | Placebo will match L606 but contain no treprostinil. |
| L606 inhalation suspension | COMBINATION_PRODUCT | L606 inhalation suspension |
Inclusion Criteria: * Participant is between 18 years to 80 years old. * Has a confirmed diagnosis of ILD based on High Resolution Computed Tomography (HRCT) chest imaging. * Evidence of PH as demonstrated from Right Heart Catheterization (RHC) with the following hemodynamic parameters: * Pulmonary...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 5 | PHASE3 | selexipag, Macitentan |
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| IRulya Therapeutics Inc. | IRLA | 1 | PHASE2 | LAM-001 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
L606 is an investigational inhaled formulation of treprostinil developed by Liquidia Corporation for pulmonary hypertension. It is delivered as an inhalation suspension and is being studied in Phase 3 clinical trials for pulmonary arterial hypertension and pulmonary hypertension due to lung disease. It has not been approved by the FDA.
L606 is being developed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension due to lung disease (PH-ILD). These are conditions characterized by high blood pressure in the arteries of the lungs. L606 is an inhaled formulation of treprostinil, a vasodilator that works by relaxing blood vessels in the lungs.
L606 contains treprostinil, a prostacyclin analog that targets the prostacyclin pathway. Treprostinil works by dilating pulmonary blood vessels, which lowers blood pressure in the lungs. This mechanism is used to treat pulmonary arterial hypertension and pulmonary hypertension due to lung disease.
L606 is being developed by Liquidia Corporation, which trades on the Nasdaq under the ticker LQDA. Liquidia is a biopharmaceutical company focused on therapies for pulmonary hypertension and other respiratory conditions.
L606 is in Phase 3 clinical development. It is not approved by the FDA. The Phase 3 program includes a study in pulmonary hypertension due to lung disease and a safety and tolerability study in pulmonary arterial hypertension and pulmonary hypertension due to lung disease.
L606 is being evaluated in two Phase 3 trials. NCT07285655 is a recruiting study of L606 in participants with pulmonary hypertension due to lung disease, with an estimated enrollment of 344. NCT04691154 is an active but not recruiting study of L606 in subjects with PAH or PH-ILD, with 28 participants.
Yes, L606 and L606 inhalation suspension refer to the same investigational drug product. L606 inhalation suspension is the full name that describes the formulation, which is delivered as an inhaled mist. Both names are used interchangeably in reference to Liquidia Corporation's treprostinil inhalation therapy.